{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.233","value":"76.108"},{"groupId":"OG001","spread":"20.439","value":"74.872"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Baseline Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.274","value":"0.952"},{"groupId":"OG001","spread":"14.919","value":"-0.238"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Change at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.797","value":"-1.152"},{"groupId":"OG001","spread":"22.557","value":"-10.227"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Change at Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.577","value":"-2.193"},{"groupId":"OG001","spread":"13.176","value":"-8.333"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Change at Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.641","value":"-5.625"},{"groupId":"OG001","spread":"16.017","value":"-10.185"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Change at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.087","value":"-10.185"},{"groupId":"OG001","spread":"6.972","value":"-4.167"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Change at Cycle 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.429","value":"0.758"},{"groupId":"OG001","spread":"5.893","value":"-4.167"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at Cycle 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.936","value":"-2.381"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.720","value":"-8.333"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.911","value":"-10.417"},{"groupId":"OG001","spread":"23.148","value":"-10.539"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Change at EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"Global health status and quality of life was assessed using the EORTC QLQ-C30 questionnaire. The score range for the EORTC QLQ-C30 is from 0 to 100, with higher scores indicating better functioning and better global health status and health-related quality of life. A positive change indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Tebentafusp administered at 20 mcg at Cycle 1 Day 1, 30 mcg at Cycle 1 Day 8, and 68 mcg at Cycle 1 Day 15 by IV infusion and weekly thereafter.","id":"OG000","title":"Tebentafusp"},{"description":"1 of 3 Investigator's Choice options: Systemic Dacarbazine, Ipilimumab or Pembrolizumab. Dacarbazine: administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity; Ipilimumab: administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments; Pembrolizumab: administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity.","id":"OG001","title":"Investigator's Choice"}],"paramType":"MEAN","populationDescription":"The Intent-to-treat (ITT) Analysis Set comprises all participants assigned to treatment analyzed by the treatment assignment whether or not the participant received the assigned treatment. Combining participants into a single group as part of the Investigator's Choice arm was pre-specified as part of the study design; therefore, data per different treatments were not analyzed.","reportingStatus":"POSTED","timeFrame":"EORTC QLQ-C30 was assessed at baseline (Cycle 1 Day 1) and on Day 1 of every other cycle to Cycle 5 Day 1, every fourth cycle thereafter, beginning with Cycle 9 Day 1 and End of Treatment (EOT), up to 36 months. Each cycle is 21 days.","title":"Quality-of-Life: Change From Baseline in EORTC QLQ-C30 Global Health Status","type":"SECONDARY","unitOfMeasure":"Units on a scale"}